Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

Dec 11, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

Nov 14, 2023

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

Nov 2, 2023

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Oct 25, 2023

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

Oct 19, 2023

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

Oct 2, 2023

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Sep 12, 2023

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

Aug 22, 2023

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

Jul 24, 2023